HIKAL Annual Report is a must read for everyone tracking the CDMO/API/Intermediates industry.
HIKAL being a hybrid player, their Annual Report insights on Pharma, Animal Health and Crop
More from Saket Reddy
MINDTREE
Double Top Buy above 2233.36 daily close on 1% Box size chart. https://t.co/Grtz9Pi3vU
Double Top Buy above 2233.36 daily close on 1% Box size chart. https://t.co/Grtz9Pi3vU
MINDTREE
— Saket Reddy (@saketreddy) December 22, 2020
The company is an international information technology consulting and implementation organisation that delivers business solutions through global software development.
DTB above 1619.22 daily close on 3% box size chart, DTB active on 1% chart. https://t.co/dhQmouQ9Wt pic.twitter.com/g8Rgz7fA0A
HAVELLS
Double Top Buy above 1485.56 daily close on 1% Box Size chart. https://t.co/zY8JwRIZUu
Double Top Buy above 1485.56 daily close on 1% Box Size chart. https://t.co/zY8JwRIZUu
HAVELLS
— Saket Reddy (@saketreddy) August 30, 2021
Double Top Buy, Super Pattern - Bullish & T20 Pattern - Bullish above 1266.91 daily close on 1% Box Size chart. https://t.co/78Tb2dKZkm pic.twitter.com/4lWz25jGgk
More from Hikal
Key insights from Hikal
🧪 Lowered interest rates
🧪 Pharma: Growth in generics as well as CDMO
🧪 Crop Protection: Scaleup of a fungicide for a Japanese CDMO client
🧪 Healthy pipeline of new products: Supported by new capacities; Investing in Animal Health & Biocides verticals https://t.co/D70j9oriCa
🧪 Lowered interest rates
🧪 Pharma: Growth in generics as well as CDMO
🧪 Crop Protection: Scaleup of a fungicide for a Japanese CDMO client
🧪 Healthy pipeline of new products: Supported by new capacities; Investing in Animal Health & Biocides verticals https://t.co/D70j9oriCa
Hikal: Strong
— JST Investments (@JstInvestments) August 5, 2021
\U0001f9ea Rev up 27% YoY
\U0001f9ea 22% EBITDA margin
\U0001f9ea Pat of 50crs
\U0001f9ea Growth across both pharmaceuticals & crop protection.#Q1withJST #Pharma pic.twitter.com/8lFo68KzPe